San Diego-based Sorrento Therapeutics has named William Marth, the former President and CEO of Teva - Americas, as the company's new Chairman, the company said Thursday. The company, which is developing treatments for cancer, said Marth was behind the acquisition of Cephalon and Barr Pharmaceuticals while he was at Teva, and also has served at Bristol-Myers Squibb, Albany Molecular Research, and other companies. In related news, David R. Webb, Ph.D. has stepped down from the board.
Top NewsFriday, January 10, 2014
Sorrento Therapeutics Names New Chairman